李艳萍 博士 副研究员（博士生导师）
单位：四川大学华西医院
通讯地址：成都市武侯区科园南路88号天府生命科技园B2栋
电话/传真：15828305053
E-mail: liyanping_512@163.com
简历
2006.09～2010.06 四川大学华西药学院，学士
2010.09～2015.06 四川大学华西药学院，博士
2015.07～2017.08 四川大学华西医院，助理研究员
2017.01～2019.06 四川大学，专职博士后（在职）
2017.09～至今 四川大学华西医院，副研究员
研究方向
靶向药物递释系统的构建及评价，代谢性疾病的发病机制与药物治疗
主要研究课题
1. 国家自然科学基金面上项目，肠道β-1,3半乳糖基转移酶5在非酒精性脂肪性肝炎调控中的作用及机制，批准编号：82170874，执行年限：2022.01-2025.12，主持；
2. 国家自然科学基金面上项目，Sirt6调节TGF-beta信号通路及其在肝脏疾病中的作用机制研究，批准编号：81870599，执行年限：2019.01-2022.12，主持；
3. 国家自然科学基金青年基金，基于前药原理设计、整合素受体介导的脑肿瘤靶向聚合物胶束递药系统研究，批准编号：81603035，执行年限：2019.01-2022.12，主持；
4. 四川省科技厅重点研发项目，整合素受体介导的活化肝星状细胞靶向多功能纳米胶束的构建及用于肝纤维化精准治疗的研究，批准编号：2020YFS0064，执行年限：2020.01-2021.12，主持；
5. 中国博士后科学基金特别资助，整合素受体介导的活化肝星状细胞靶向递药系统研究，批准编号：2018T110986，执行年限：2018.06-2020.03，主持；
6. 中国博士后科学基金面上资助，整合素受体介导的多功能脑肿瘤靶向递药系统的研究，批准编号：2017M612981，执行年限：2017.05-2018.12，负责人；
7. 四川大学专职博士后研发基金，整合素受体介导的活化HSCs靶向多功能聚合物胶束用于肝纤维化精准治疗的研究，批准编号：2017SCU12036，执行年限：2017.08-2018.12，主持；
8. 四川大学青年教师启动基金，基于前药原理设计、整合素受体介导的脑肿瘤靶向聚合物胶束递药系统研究，批准编号：2017SCU11026，执行年限：2017.01-2018.12，主持；
9. 四川省卫计委资助，吡柔比星聚合物胶束用于治疗多药耐药乳腺癌的研究，批准编号：16PJ330，执行年限：2016.01-2017.12，主持；
10. 四川大学华西医院专职博士后研发基金，Sirt6调节TGF-β信号通路及其在肝纤维化中的作用机制研究，批准编号：2018HXBH060，执行年限：2019.01-2020.12，主持。
代表论著
1. Zhang J*, Li Y*, Liu Q, Huang Y, Li R, Wu T, Zhang Z, Zhou J, Huang H, Tang Q, Huang C, Zhao Y, Zhang G, Jiang W, Mo L, Zhang J, Xie W, He J#: Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells. Hepatology 2021, 73(3):1140-1157.
2. Huang C, Liu Q, Tang Q, Jing X, Wu T, Zhang J, Zhang G, Zhou J, Zhang Z, Zhao Y, Huang H, Xia Y, Yan J, Xiao J#, Li Y#, He J#: Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis. Free Radic Biol Med 2021, 169:110-121.
3. Huang H, Liu Q, Zhang T, Zhang J, Zhou J, Jing X, Tang Q, Huang C, Zhang Z, Zhao Y, Zhang G, Yan J, Xia Y, Xu Y, Li J, Li Y#, He J: Farnesylthiosalicylic Acid-Loaded Albumin Nanoparticle Alleviates Renal Fibrosis by Inhibiting Ras/Raf1/p38 Signaling Pathway. Int J Nanomedicine 2021, 16:6441-6453.
4. Zhou J, Li R, Zhang JH, Liu QH, Wu T, Tang Q, Huang CY, Zhang ZJ, Huang Y, Huang H, Zhang GR, Zhao YN, Zhang T, Mo L, Li Y#, He J#: Targeting Interstitial Myofibroblast-Expressed Integrin alpha v beta 3 Alleviates Renal Fibrosis. Mol Pharm 2021, 18(3): 1373-1385.
5. Zhang J, Liu Q, He J#, Li Y#: Novel therapeutic targets in liver fibrosis. Front Mol Biosci 2021, 8:766855.
6. Zhou J, Li R, Liu Q, Zhang J, Huang H, Huang C, Zhang G, Zhao Y, Wu T, Tang Q, Huang Y, Zhang Z, Li Y#, He J#: Blocking 5-LO pathway alleviates renal fibrosis by inhibiting the epithelial-mesenchymal transition. Biomed Pharmacother 2021, 138:111470.
7.Pu S*, Li Y*, Liu Q, Zhang X, Chen L, Li R, Zhang J, Wu T, Tang Q, Yang X, Zhang Z, Huang Y, Kuang J, Li H, Zou M, Jiang W, He J#: Inhibition of 5-lipoxygenase in hepatic stellate cells alleviates liver fibrosis. Front Pharmacol 2021, 12:628583
8. Li R*, Li Y*, Zhang J, Liu Q, Wu T, Zhou J, Huang H, Tang Q, Huang C, Huang Y, Zhang Z, Zhang G, Zhao Y, Ma L, Feng Y, Mo L, Han M, He J#: Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity. J Control Release 2020; 320:32-44.
9. Zhang J, Li R, Liu Q, Zhou J, Huang H, Huang Y, Zhang Z, Wu T, Tang Q, Huang C, Zhao Y, Zhang G, Mo L, Li Y#, He J#: SB431542-Loaded Liposomes Alleviate Liver Fibrosis by Suppressing TGF-β Signaling. Mol Pharm 2020;17(11):4152-4162.
10. Li Y*, Pu S*, Liu Q, Li R, Zhang J, Wu T, Chen L, Li H, Yang X, Zou M, Xiao J, Xie W#, He J#: An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. J Control Release 2019;303:77-90.
11. Li Y*, Zhang T, Liu Q, He J#: PEG-derivatized dual-functional nanomicelles for improved cancer therapy. Front Pharmacol 2019; 10:808.
12. Li Y*, Zhang T, Liu Q, Zhang J, Li R, Pu S, Wu T, Ma L, He J#: Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of nonalcoholic steatohepatitis. Int J Nanomed 2019;14:3943-3953.
13. Zhang J*, Li Y*, Liu Q, Li R, Pu S, Yang L, Feng Y, Ma L#: SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway. RSC Adv 2018;8:30919-30924.
14. Li H*, Li Y*, Wang X, Hou Y, Hong X, Gong T, Zhang Z, Sun X#: Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy. Theranostics 2017;7:4383-4398.
15. Li Y*, Li R*, Liu Q, Li W, Zhang T, Zou M, Li H, Wu T, Cheng S, Su Z, Zhang Z, He J#: One-Step Self-Assembling Nanomicelles for Pirarubicin Delivery To Overcome Multidrug Resistance in Breast Cancer. Mol Pharm 2016;13:3934-3944.
16. Li Y*, Liu Q, Li W, Zhang T, Li H, Li R, Chen L, Pu S, Kuang J, Su Z, Zhang Z, He J#: Design and Validation of PEG-Derivatized Vitamin E Copolymer for Drug Delivery into Breast Cancer. Bioconjug Chem 2016;27:1889-1899.
17. Li Y*, Zhou Y, Jiang J, Wang X, Fu Y, Gong T, Sun X, Zhang Z#: Mechanism of brain targeting by dexibuprofen prodrugs modified with ethanolamine-related structures. J Cereb Blood Flow Metab 2015;35:1985-1994.
18. Li Y*, Zhou Y, Qi B, Gong T, Sun X, Fu Y, Zhang Z#: Brain-specific delivery of dopamine mediated by n,n-dimethyl amino group for the treatment of Parkinson's disease. Mol Pharm 2014;11:3174-3185.
19. Lin Y*, Li Y*, Wang X, Gong T, Zhang L#, Sun X#: Targeted drug delivery to renal proximal tubule epithelial cells mediated by 2-glucosamine. J Control Release 2013;167:148-156.
授权专利
1. 何金汗，李艳萍，莫莉，靶向棕色脂肪组织的递药系统，201810050344.1，2021.01.04授权，中国发明专利。
2. 何金汗，李艳萍，马良，莫莉，SKLB023 混合胶束及其制备方法和用途， 201811391951.0，2021.05.11授权，中国发明专利。
